免疫检查点抑制剂诱发的血栓性血小板减少性紫癜：一例报告及文献复习
Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature.
作者信息
Ali Zeeshan, Zafar Muhammad Usman, Wolfe Zachary, Akbar Faisal, Lash Bradley
机构信息
Hematology and Oncology, Lehigh Valley Health Network, Allentown, USA.
Hospital Medicine, Lehigh Valley Health Network, Allentown, USA.
出版信息
Cureus. 2020 Oct 29;12(10):e11246. doi: 10.7759/cureus.11246.
Abstract
In recent years, the role of immune checkpoint inhibitors (ICI) in cancer treatment has rapidly expanded. In randomized clinical trials, these agents have demonstrated clinical efficacy in extending survival and increasing response rates. Immune-related adverse effects (irAEs) involving various organs have been frequently narrated. Herein, we present a case report of thrombotic thrombocytopenic purpura (TTP) as a rare side effect of nivolumab, plus ipilimumab, in the treatment of metastatic renal cell carcinoma (RCC). A review of the literature for other case reports of TTP during treatment with ICIs was also performed. Our aim is to elucidate the significance of early recognition of this rare adverse effect in patients being treated with this relatively newer class of medications.
摘要
近年来，免疫检查点抑制剂（ICI）在癌症治疗中的作用迅速扩大。在随机临床试验中，这些药物已显示出延长生存期和提高缓解率的临床疗效。涉及多个器官的免疫相关不良反应（irAE）屡有报道。在此，我们报告一例血栓性血小板减少性紫癜（TTP）病例，这是纳武单抗联合伊匹木单抗治疗转移性肾细胞癌（RCC）时罕见的副作用。我们还对ICI治疗期间TTP的其他病例报告进行了文献综述。我们的目的是阐明在使用这类相对较新的药物治疗的患者中早期识别这种罕见不良反应的重要性。
相似文献
1
Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature.免疫检查点抑制剂诱发的血栓性血小板减少性紫癜：一例报告及文献复习
Cureus. 2020 Oct 29;12(10):e11246. doi: 10.7759/cureus.11246.
2
Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.病例报告：Ipilimumab 和 Nivolumab 联合免疫疗法治疗转移性黑色素瘤后发生血栓性血小板减少性紫癜。
Front Immunol. 2022 Apr 20;13:871217. doi: 10.3389/fimmu.2022.871217. eCollection 2022.
3
Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer.一名转移性非小细胞肺癌患者发生免疫检查点抑制剂相关血栓性血小板减少性紫癜
Cureus. 2021 Jun 29;13(6):e16035. doi: 10.7759/cureus.16035. eCollection 2021 Jun.
4
Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.纳武单抗诱发的胃管癌患者血栓性血小板减少性紫癜
Intern Med. 2024 Oct 1;63(19):2667-2671. doi: 10.2169/internalmedicine.2931-23. Epub 2024 Mar 4.
5
Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.获得性血栓性血小板减少性紫癜与免疫检查点抑制剂相关：FDA 不良事件报告系统的真实世界研究。
Int Immunopharmacol. 2022 Sep;110:109015. doi: 10.1016/j.intimp.2022.109015. Epub 2022 Jul 6.
6
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.由检查点抑制剂引起的血栓性血小板减少性紫癜
Case Rep Hematol. 2018 Dec 20;2018:2464619. doi: 10.1155/2018/2464619. eCollection 2018.
7
Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.卡泊单抗成功治疗难治性自身免疫性血栓性血小板减少性紫癜
Front Med (Lausanne). 2020 Oct 22;7:549931. doi: 10.3389/fmed.2020.549931. eCollection 2020.
8
Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.一名已知患有特发性（免疫性）血小板减少性紫癜的患者发生产后血栓性血小板减少性紫癜：病例报告及文献综述
J Med Case Rep. 2018 Jun 1;12(1):147. doi: 10.1186/s13256-018-1692-1.
9
Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab.接受卡泊单抗治疗的血栓性血小板减少性紫癜患者的延迟性血栓并发症
J Hematol. 2020 Sep;9(3):84-88. doi: 10.14740/jh614. Epub 2020 Aug 14.
10
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
引用本文的文献
1
A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor-Related Acquired Thrombotic Thrombocytopenic Purpura.一种罕见但致命的毒性：免疫检查点抑制剂相关的获得性血栓性血小板减少性紫癜。
J Immunother Precis Oncol. 2025 Jan 10;8(1):15-22. doi: 10.36401/JIPO-24-2. eCollection 2025 Feb.
2
Systemic Lupus Erythematosus (SLE) and Thrombotic Thrombocytopenic Purpura (TTP) Presenting as Recurrent Strokes: A Case Report.系统性红斑狼疮（SLE）和血栓性血小板减少性紫癜（TTP）表现为复发性中风：一例报告
Cureus. 2024 May 13;16(5):e60238. doi: 10.7759/cureus.60238. eCollection 2024 May.
3
Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.纳武单抗诱发的胃管癌患者血栓性血小板减少性紫癜
Intern Med. 2024 Oct 1;63(19):2667-2671. doi: 10.2169/internalmedicine.2931-23. Epub 2024 Mar 4.
4
Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge.免疫检查点抑制剂诱发的肾毒性：一项持续存在的挑战。
Front Med (Lausanne). 2022 Dec 20;9:1014257. doi: 10.3389/fmed.2022.1014257. eCollection 2022.
5
Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy.老调重弹：免疫治疗癌症患者出现血栓栓塞并发症。
Thromb Res. 2022 May;213(Suppl 1):S51-S57. doi: 10.1016/j.thromres.2022.01.006. Epub 2022 May 26.
6
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?用于治疗检查点抑制剂引起的严重免疫相关不良事件的血浆置换：一个早期的机会窗口？
Immunother Adv. 2022 May 27;2(1):ltac012. doi: 10.1093/immadv/ltac012. eCollection 2022.
7
Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature.基于mRNA的COVID-19疫苗BNT162b2接种后免疫介导的血栓性血小板减少性紫癜：病例报告及文献综述
Front Med (Lausanne). 2022 May 17;9:890661. doi: 10.3389/fmed.2022.890661. eCollection 2022.
8
The Efficacy and Safety of Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic Purpura.血浆置换治疗血栓性血小板减少性紫癜的疗效和安全性。
J Healthc Eng. 2022 Mar 31;2022:3519937. doi: 10.1155/2022/3519937. eCollection 2022.
9
The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.血管性血友病因子、ADAMTS13与癌症之间的有趣联系。
Healthcare (Basel). 2022 Mar 16;10(3):557. doi: 10.3390/healthcare10030557.
10
A Rare Association of Thrombotic Thrombocytopenic Purpura with Systemic Lupus Erythematosus in a Sudanese Woman: Case Report.一名苏丹女性患血栓性血小板减少性紫癜与系统性红斑狼疮的罕见关联：病例报告
J Blood Med. 2021 Nov 6;12:945-949. doi: 10.2147/JBM.S334689. eCollection 2021.
本文引用的文献
1
Pembrolizumab-induced thrombotic thrombocytopenic purpura.帕博利珠单抗诱发的血栓性血小板减少性紫癜。
J Oncol Pharm Pract. 2020 Jul;26(5):1237-1240. doi: 10.1177/1078155219887212. Epub 2019 Nov 13.
2
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.由检查点抑制剂引起的血栓性血小板减少性紫癜
Case Rep Hematol. 2018 Dec 20;2018:2464619. doi: 10.1155/2018/2464619. eCollection 2018.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
5
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.纳武利尤单抗辅助治疗与伊匹单抗用于切除的 III 期或 IV 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
6
Pathophysiology of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的病理生理学
Blood. 2017 Sep 7;130(10):1181-1188. doi: 10.1182/blood-2017-04-636431. Epub 2017 Aug 2.
7
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP).伊匹单抗诱导的血栓性血小板减少性紫癜（TTP）。
J Immunother Cancer. 2017 Mar 21;5:19. doi: 10.1186/s40425-017-0224-7. eCollection 2017.
8
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.不符合临床试验入选标准的转移性肾细胞癌患者的结局。
Ann Oncol. 2014 Jan;25(1):149-54. doi: 10.1093/annonc/mdt492.
9
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.接受血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者总生存的预后因素：一项大型多中心研究的结果
J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.
10
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.670例晚期肾细胞癌患者的生存情况及预后分层
J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.
Zotero 插件